Hurel microlivers are self-assembling co-cultures (SACCs) of primary cryopreserved hepatocytes. This patented form of liver cell culture has been shown, in peer-reviewed studies, to produce the longest-enduring, phenotypically stable, metabolically most competent of any advanced liver tissue construct developed in the world to date.
Hurel makes patented co-cultures—“microlivers”—that elevate the metabolic competency, the enduring viability, and the dynamic cellular responsiveness of hepatocytes cultured in vitro. These qualities endow Hurel with an unrivaled degree of predictive sensitivity—human relevance®—and make Hurel the gold standard of advanced liver tissue constructs.
Hurel’s well-characterized use cases include preclinical assessment of clearance rates of metabolically stable compounds, metabolite generation and identification, induction and inhibition of enzymatic action, biliary efflux of chemical entities; prediction of general cytotoxicity and hepatoxicity, mitochondrial toxicity, cholestatic liability, hepatotoxicity arising from the formation of reactive metabolites; and the study of viral replication underlying hepatotropic disease.
Hurel’s products and services have been adopted by top-ranking pharma and biotech firms in the United States, Europe, and around the world.